And Dong-A Pharmaceutical has taken the first ranking In the growth rate of ETC sales compared to the same period of 2008.
Health Korea News, one of the Korea major online news papers released on 17 July its data analysis based on prescription data of ETC for the first half of 2009.
According to this analysis, Daewoong Pharmaceutical214.9 billion won) has ranked top in ETC sales, followed by Handok Pharmaceuticals(203.5 "), Hanmi Pharmaceutical(200.9 "), Dong-A Pharmaceutical(194.3 "), Yuhan Corporation(139.4 "), Chong Kun Dang Pharm(126.4 "), ILDONG Pharmaceutical(84.6 “) and Choongwae Pharma Corporation(72.1 ").
In the growth rate of ETC sales compared to the same period of 2008, Dong-A Pharmaceutical and Chong Kun Dang Pharm have showed an increase of 34.57% and 30.18% respectively, followed by Yuhan Cirporation(19.62%), Hanmi Pharmaceutical(14.20%), Daewoong Pharmaceutical(7.68%) and Choongwae Pharma Corporation(6.72%).
Among the multinational drugmakers, Pfizer Korea Inc. has ranked top(164.0 billion won) in ETC sales, followed by GSK Korea(133.2 "), MSD Korea(114.8 ") and Novartis Korea(109.1 ").<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
